HOTH - Hoth Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.5100
-0.5869 (-11.51%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.0969
Open4.6000
Bid4.6000 x 800
Ask7.0000 x 800
Day's Range4.5100 - 4.6000
52 Week Range4.5100 - 13.8800
Volume601
Avg. Volume20,443
Market Cap42.511M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4960
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Hoth Therapeutics, Inc. to Ring NASDAQ Closing Bell on April 22, 2019
    PR Newswire4 days ago

    Hoth Therapeutics, Inc. to Ring NASDAQ Closing Bell on April 22, 2019

    "Ringing the NASDAQ closing bell following our initial public offering to the exchange in February of this year, highlights what an exciting time it is at the company," stated Mr. Robb Knie, CEO of Hoth Therapeutics.

  • Hoth Therapeutics, Inc. Announces the Addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board
    PR Newswire14 days ago

    Hoth Therapeutics, Inc. Announces the Addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board

    NEW YORK, April 8, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Lawrence A. Schachner, M.D. and Dr. Vincent C.O. Njar, Ph.D. to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • Hoth Therapeutics, Inc. Announces the Addition of Dr. Stefanie Johns, Ph.D. to the Company's Scientific Advisory Board
    PR Newswirelast month

    Hoth Therapeutics, Inc. Announces the Addition of Dr. Stefanie Johns, Ph.D. to the Company's Scientific Advisory Board

    NEW YORK, March 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH),  a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced the addition of Dr. Stefanie Johns  to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform and other therapeutics.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.
    PR Newswirelast month

    Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc.

    Hoth secures exclusive rights to develop and commercialize therapeutic compounds for dermatological treatments Lead compounds show potent in vivo anti-cancer activity Lead compounds show promise in vitro ...

  • Hoth Therapeutics Announces Dr. Jonathan Zippin as Senior Scientific Advisor
    PR Newswirelast month

    Hoth Therapeutics Announces Dr. Jonathan Zippin as Senior Scientific Advisor

    Zippin will advise Hoth Therapeutics on trial design, development and implementation of BioLexa for Atopic Dermatitis NEW YORK , March 11, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a ...

  • Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center
    PR Newswire2 months ago

    Hoth Therapeutics, Inc. to Begin Pilot Study at Massachusetts General Hospital Vaccine and Immunotherapy Center

    Study will aim to determine the efficacy of the BioLexa Platform in the context of chronic diabetic ulcers, with and without substantial bacterial burden. NEW YORK , March 4, 2019 /PRNewswire/ -- Hoth ...

  • GlobeNewswire2 months ago

    Hoth Therapeutics Inc. Announces the Addition of Dr. Adam Friedman, M.D. to the Company's Scientific Advisory Board

    Hoth Therapeutics, Inc.(HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the addition of Dr. Adam Friedman, M.D., to the Company's Scientific Advisory Board.  The Scientific Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • GlobeNewswire2 months ago

    Hoth Therapeutics Inc. Announces Closing of Initial Public Offering

    Hoth Therapeutics Inc. (HOTH), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share, resulting in aggregate gross proceeds of $7.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Hoth has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.

  • GlobeNewswire2 months ago

    Hoth Therapeutics Inc. Announces Pricing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “HOTH”

    Hoth Therapeutics Inc. (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments, if any.